ASBS: Cryoablation Promising for Early Invasive Breast Cancer
Cryoablation successful in 69 percent of early-stage invasive ductal breast cancers
WEDNESDAY, April 30, 2014 (HealthDay News) -- Cryoablation seems to be a promising therapeutic option for early-stage invasive ductal breast cancers (IFDC), according to a study presented at the annual meeting of the American Society of Breast Surgeons, held from April 30 to May 4 in Las Vegas.
Rache Simmons, M.D., from the Weill Cornell Breast Center in New York City, and colleagues conducted a phase II trial to explore the effectiveness of cryoablation in the treatment of early-stage IFDC in 86 patients (87 breast cancers). A cryoprobe was inserted percutaneously into the targeted lesion and patients underwent ablation using a freeze-thaw-freeze cycle.
The researchers found that in pathologic assessment, cryoablation was successful in 69.0 percent of cancers, and residual IFDC and/or ductal carcinoma in situ (DCIS) were seen in 31.0 percent of cancers. Using a definition of successful cryoablation as no residual IFDC, 80.5 percent of cancers showed successful cryoablation. Using a definition of no residual IFDC/DCIS or enhancement on the post-ablation magnetic resonance imaging, 75.9 percent of breasts underwent successful cryoablation and 24.1 percent were failures.
"Clearly the benefits of cryoablation for breast cancer treatment are numerous. This study shows that it can be quite effective," Simmons said in a statement. "Possibly some women may be able to take advantage of the technique within the next few years by participating in a trial of cryoablation used without follow-up surgery -- perhaps even sooner."